The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells

被引:5
作者
Sennoune, Souad R. [1 ]
Nelius, Thomas [1 ]
Jarvis, Courtney [2 ]
Pruitt, Kevin [2 ]
Kottapalli, Kameswara Rao [3 ]
Filleur, Stephanie [1 ,2 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Dept Urol, Lubbock, TX 79430 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Dept Immunol & Mol Microbiol, Lubbock, TX 79430 USA
[3] Amer Univ Antigua, Coll Med, West Indies, Antigua, West Indies, Antigua & Barbu
来源
PLOS ONE | 2020年 / 15卷 / 06期
关键词
PLUS PREDNISONE; RESISTANT; DOCETAXEL; RECEPTOR; TAXANE; NANOPARTICLES; CHEMOTHERAPY; MITOXANTRONE; PATHWAY; TRIAL;
D O I
10.1371/journal.pone.0234078
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Despite new drugs, metastatic prostate cancer remains fatal. Growing interest in the latest approved cabazitaxel taxane drug has markedly increased due to the survival benefits conferred when used at an earlier stage of the disease, its promising new therapeutic combination and formulation, and its differential toxicity. Still cabazitaxel's mechanisms of resistance are poorly characterized. The goal of this study was thus to generate a new model of acquired resistance against cabazitaxel in order to unravel cabazitaxel's resistance mechanisms. Methods Du145 cells were cultured with increasing concentrations of cabazitaxel, docetaxel/ taxane control or placebo/age-matched control. Once resistance was reached, Epithelial-to-Mesenchymal Translation (EMT) was tested by cell morphology, cell migration, and E/M markers expression profile. Cell transcriptomics were determined by RNA sequencing; related pathways were identified using IPA, PANTHER or KEGG software. The Wnt pathway was analyzed by western blotting, pharmacological and knock-down studies. Results While age-matched Du145 cells were sensitive to both taxane drugs, docetaxel-resistant cells were only resistant to docetaxel and cabazitaxel-resistant cells showed a partial crossresistance to both drugs concomitant to EMT. Using RNA-sequencing, the Wnt non-canonical pathway was identified as exclusively activated in cabazitaxel resistant cells while the Wnt canonical pathway was restricted to docetaxel-resistant cells. Cabazitaxel-resistant cells showed a minimal crossover in the Wnt-pathway-related genes linked to docetaxel resistance validating our unique model of acquired resistance to cabazitaxel. Pharmacological and western blot studies confirmed these findings and suggest the implication of the Tyrosine kinase Ror2 receptor in cabazitaxel resistant cells. Variation in Ror2 expression level altered the sensitivity of prostate cancer cells to both drugs identifying a possible new target for taxane resistance. Conclusion Our study represents the first demonstration that while Wnt pathway seems to play an important role in taxanes resistance, Wnt effectors responsible for taxane specificity remain un-identified prompting the need for more studies.
引用
收藏
页数:22
相关论文
共 87 条
  • [1] Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer
    Al-Mansouri, Loma
    Gurney, Howard
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (06) : 288 - 295
  • [2] Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial
    Angel Climent, Miguel
    Perez-Valderrama, Begona
    Mellado, Begona
    Fernandez Parra, Eva Maria
    Fernandez Calvo, Ovidio
    Ochoa de Olza, Maria
    Muinelo Romay, Laura
    Anido, Urbano
    Domenech, Montserrat
    Hernando Polo, Susana
    Arranz Arija, Jose Angel
    Caballero, Cristina
    Juan Fita, Maria Jose
    Castellano, Daniel
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 87 : 30 - 37
  • [3] Human cardiac stem cells
    Bearzi, Claudia
    Rota, Marcello
    Hosoda, Toru
    Tillmanns, Jochen
    Nascirnbene, Angelo
    De Angelis, Antonella
    Yasuzawa-Amano, Saori
    Trofimova, Irina
    Siggins, Robert W.
    LeCapitaine, Nicole
    Cascapera, Stefano
    Beltrami, Antonio P.
    D'Alessandro, David A.
    Zias, Elias
    Quaini, Federico
    Urbanek, Konrad
    Michler, Robert E.
    Bolli, Roberto
    Kajstura, Jan
    Leri, Annarosa
    Anversa, Piero
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (35) : 14068 - 14073
  • [4] A Switch from Canonical to Noncanonical Wnt Signaling Mediates Drug Resistance in Colon Cancer Cells
    Bordonaro, Michael
    Tewari, Shruti
    Cicco, Catherine E.
    Atamna, Wafa
    Lazarova, Darina L.
    [J]. PLOS ONE, 2011, 6 (11):
  • [5] Nanoparticle Formulation Derived from Carboxymethyl Cellulose, Polyethylene Glycol, and Cabazitaxel for Chemotherapy Delivery to the Brain
    Bteich, Joseph
    Ernsting, Mark J.
    Mohammed, Mohammed
    Kiyota, Taira
    McKee, Trevor D.
    Trikha, Mohit
    Lowman, Henry B.
    Sokoll, Kenneth K.
    [J]. BIOCONJUGATE CHEMISTRY, 2018, 29 (06) : 2009 - 2020
  • [6] The STAMPEDE trial: paradigm-changing data through innovative trial design
    Carthon, Bradley C.
    Antonarakis, Emmanuel S.
    [J]. TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S485 - S490
  • [7] Chen RG, 2018, AM J CANCER RES, V8, P1297
  • [8] Cabazitaxel liposomes with aptamer modification enhance tumor-targeting efficacy in nude mice
    Cheng, Yuzhu
    Ou, Zhanlun
    Li, Qingguo
    Yang, Juan
    Hu, Min
    Zhou, Yubin
    Zhuang, Xiaodong
    Zhang, Zhenyu Jason
    Guan, Shixia
    [J]. MOLECULAR MEDICINE REPORTS, 2019, 19 (01) : 490 - 498
  • [9] Corn PG, 2019, LANCET ONCOL
  • [10] Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
    Darshan, Medha S.
    Loftus, Matthew S.
    Thadani-Mulero, Maria
    Levy, Benjamin P.
    Escuin, Daniel
    Zhou, Xi Kathy
    Gjyrezi, Ada
    Chanel-Vos, Chantal
    Shen, Ruoqian
    Tagawa, Scott T.
    Bander, Neil H.
    Nanus, David M.
    Giannakakou, Paraskevi
    [J]. CANCER RESEARCH, 2011, 71 (18) : 6019 - 6029